These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 27312728)

  • 1. Failed trials for central nervous system disorders do not necessarily invalidate preclinical models and drug targets.
    Bespalov A; Steckler T; Altevogt B; Koustova E; Skolnick P; Deaver D; Millan MJ; Bastlund JF; Doller D; Witkin J; Moser P; O'Donnell P; Ebert U; Geyer MA; Prinssen E; Ballard T; Macleod M
    Nat Rev Drug Discov; 2016 Jul; 15(7):516. PubMed ID: 27312728
    [No Abstract]   [Full Text] [Related]  

  • 2. Consider drug efficacy before first-in-human trials.
    Kimmelman J; Federico C
    Nature; 2017 Jan; 542(7639):25-27. PubMed ID: 28150789
    [No Abstract]   [Full Text] [Related]  

  • 3. Preclinical research: Make mouse studies work.
    Perrin S
    Nature; 2014 Mar; 507(7493):423-5. PubMed ID: 24678540
    [No Abstract]   [Full Text] [Related]  

  • 4. Overview on 5-HT receptors and their role in physiology and pathology of the central nervous system.
    Filip M; Bader M
    Pharmacol Rep; 2009; 61(5):761-77. PubMed ID: 19903999
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug development: Raise standards for preclinical cancer research.
    Begley CG; Ellis LM
    Nature; 2012 Mar; 483(7391):531-3. PubMed ID: 22460880
    [No Abstract]   [Full Text] [Related]  

  • 6. Recommended guidelines for studies of human subjects with spinal cord injury.
    Anderson DK; Beattie M; Blesch A; Bresnahan J; Bunge M; Dietrich D; Dietz V; Dobkin B; Fawcett J; Fehlings M; Fischer I; Grossman R; Guest J; Hagg T; Hall ED; Houle J; Kleitman N; McDonald J; Murray M; Privat A; Reier P; Steeves J; Steward O; Tetzlaff W; Tuszynski MH; Waxman SG; Whittemore S; Wolpaw J; Young W; Zheng B
    Spinal Cord; 2005 Aug; 43(8):453-8. PubMed ID: 15824756
    [No Abstract]   [Full Text] [Related]  

  • 7. Exploratory clinical testing of neuroscience drugs.
    Choi DW
    Nat Neurosci; 2002 Nov; 5 Suppl():1023-5. PubMed ID: 12403975
    [No Abstract]   [Full Text] [Related]  

  • 8. Designing prospective clinical pharmacogenomic (PG) trials: meeting report on drug development strategies to enhance therapeutic decision making.
    Trepicchio WL; Essayan D; Hall ST; Schechter G; Tezak Z; Wang SJ; Weinreich D; Simon R
    Pharmacogenomics J; 2006; 6(2):89-94. PubMed ID: 16402088
    [No Abstract]   [Full Text] [Related]  

  • 9. Central nervous system drug development, basic, and clinical research: thinking outside the box.
    Klein DF; Glick ID; Shader RI
    J Clin Psychopharmacol; 2011 Oct; 31(5):553-4. PubMed ID: 21869701
    [No Abstract]   [Full Text] [Related]  

  • 10. Translational medicine 2006.
    Persiani S
    IDrugs; 2006 Apr; 9(4):253-5. PubMed ID: 16596476
    [No Abstract]   [Full Text] [Related]  

  • 11. Guidelines for preclinical and early phase clinical assessment of novel radiosensitisers.
    Harrington KJ; Billingham LJ; Brunner TB; Burnet NG; Chan CS; Hoskin P; Mackay RI; Maughan TS; Macdougall J; McKenna WG; Nutting CM; Oliver A; Plummer R; Stratford IJ; Illidge T
    Br J Cancer; 2011 Aug; 105(5):628-39. PubMed ID: 21772330
    [No Abstract]   [Full Text] [Related]  

  • 12. An FDA oncology view of juvenile animal studies in support of initial pediatric trials for anticancer drugs.
    Leighton JK; Saber H; Reaman G; Pazdur R
    Regul Toxicol Pharmacol; 2016 Aug; 79():142-143. PubMed ID: 26952647
    [No Abstract]   [Full Text] [Related]  

  • 13. Selecting promising ALS therapies in clinical trials.
    Glass JD; Benatar M; Polak M
    Neurology; 2007 May; 68(18):1545-6; author reply 1546. PubMed ID: 17470765
    [No Abstract]   [Full Text] [Related]  

  • 14. SOP 01: Clinical investigations in CESAR.
    Onkologie; 2003 Oct; 26 Suppl 6():1-4. PubMed ID: 23570177
    [No Abstract]   [Full Text] [Related]  

  • 15. Quality assurance of clinical studies with production drugs.
    McCormack JF
    Qual Assur; 1997; 5(1):55-9. PubMed ID: 9170175
    [No Abstract]   [Full Text] [Related]  

  • 16. Translational research in central nervous system drug discovery.
    Hurko O; Ryan JL
    NeuroRx; 2005 Oct; 2(4):671-82. PubMed ID: 16489374
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Placebo-controlled, double-blind trials.
    Walter E; Weber E
    Lancet; 1980 Jun; 1(8182):1363. PubMed ID: 6104156
    [No Abstract]   [Full Text] [Related]  

  • 18. [New animal models for the diseases of central nervous systems and screening of new drugs].
    Nabeshima T; Sasa S
    Nihon Yakurigaku Zasshi; 1997 Sep; 110(3):126-8. PubMed ID: 9327421
    [No Abstract]   [Full Text] [Related]  

  • 19. Missing results might have rung warning bell over trial drug.
    Pearson H
    Nature; 2006 Oct; 443(7113):730-1. PubMed ID: 17051171
    [No Abstract]   [Full Text] [Related]  

  • 20. The relevance of information generated by in vitro experimental models to clinical doxorubicin cardiotoxicity.
    Lipshultz SE; Cohen H; Colan SD; Herman EH
    Leuk Lymphoma; 2006 Aug; 47(8):1454-8. PubMed ID: 16966253
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.